(VIANEWS) – The Market ended the session with AB SCIENCE (AB.PA) rising 12.42% to €2.67 on Monday, following the last session’s upward trend. CAC 40 slid 0.94% to €7,068.16, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.
AB SCIENCE’s last close was €2.38, 75% under its 52-week high of €9.50.
About AB SCIENCE
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, AB SCIENCE has a trailing twelve months EPS of €-0.3.
Revenue Growth
Year-on-year quarterly revenue growth declined by 58.3%, now sitting on 958k for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AB SCIENCE’s stock is considered to be oversold (<=20).
Moving Average
AB SCIENCE’s worth is way below its 50-day moving average of €3.77 and way under its 200-day moving average of €5.72.
More news about AB SCIENCE (AB.PA).
